{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:25:06Z","timestamp":1780367106261,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Guidelines recommend initiation of dual combination antihypertensive therapy, preferably single-pill combination (SPC), in most patients with hypertension. Evidence on narrowing gaps in clinical practice relative to guidelines is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Monte Carlo simulation was applied to 1.1 million patients qualifying for dual combination therapy from a previously conducted retrospective analysis of clinical practice, hospital statistics, and national statistics in the UK. We provide 10-year Kaplan\u2013Meier event rates for the primary endpoint representing a composite of non-fatal myocardial infarction, non-fatal stroke (ischaemic or haemorrhagic), non-fatal heart failure hospitalization, or cardiovascular death. Cox model results from a previously conducted study were utilized to estimate baseline risk, together with evidence on risk reduction from the Blood Pressure Lowering Treatment Trialists\u2019 Collaboration (BPLTTC) meta-analysis and published evidence on blood pressure-lowering efficacy of antihypertensive therapies. In the overall population, estimated 10-year event rates for the primary endpoint in patients with 100% persistence in monotherapy were 17.0% for irbesartan and 17.6% for ramipril. These rates were only modestly better than those observed in clinical practice (17.8%). In patients with 100% persistence in dual therapy, estimated event rates were 13.6% for combinations of irbesartan\u00a0+\u00a0amlodipine [absolute risk reduction (ARR)\u00a0=\u00a08.7% compared with untreated] and 14.3% for ramipril\u00a0+\u00a0amlodipine (ARR\u00a0=\u00a08.0% compared with untreated). The absolute risk of the primary endpoint was reduced by 15.9% in patients with atherosclerotic cardiovascular disease (ASCVD) and 6.6% in those without ASCVD. Similarly, the absolute risk was reduced by 11.7% in patients with diabetes and 7.8% in those without diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study represents the first to investigate guidelines-based treatment in hypertensive patients and demonstrates the opportunity for considerable risk reduction by ensuring recommended dual therapy in clinical practice, particularly in the form of SPC with high persistence, relative to no treatment or monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae048","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:15:01Z","timestamp":1720581301000},"page":"697-707","source":"Crossref","is-referenced-by-count":7,"title":["Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-3266","authenticated-orcid":false,"given":"Antonio","family":"Coca","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Barcelona, Hospital Cl\u00ednic , 143 Casanova st., Barcelona 08036 ,","place":["Spain"]},{"name":"University Abat Oliba CEU , 30 Bellesguard St., Barcelona 30905 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Science and Surgery, University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S","family":"Stergiou","sequence":"additional","affiliation":[{"name":"Hypertension Center STRIDE-7, School of Medicine, Third Department of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-0904","authenticated-orcid":false,"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[{"name":"Sanofi , NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-306X","authenticated-orcid":false,"given":"Alexandra","family":"Koumas","sequence":"additional","affiliation":[{"name":"Axtria Inc. , Berkeley Heights, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-4279","authenticated-orcid":false,"given":"Jacques","family":"Blacher","sequence":"additional","affiliation":[{"name":"Diagnosis and Therapeutic Center, Universit\u00e9 Paris Cit\u00e9 H\u00f4pital H\u00f4tel-Dieu, AP-HP,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdel-Moneim","sequence":"additional","affiliation":[{"name":"Sanofi , Dubai ,","place":["United Arab Emirates"]},{"name":"Department of Family Medicine, College of Medicine, University of Sharjah ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"2025011107303549200_bib1","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025011107303549200_bib2","volume-title":"Guideline for the Pharmacological Treatment of Hypertension in Adults","author":"World Health Organization","year":"2021"},{"key":"2025011107303549200_bib3","first-page":"1334","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume-title":"Hypertension","author":"Unger","year":"2020"},{"key":"2025011107303549200_bib4","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2025011107303549200_bib5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Rahimi","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2025011107303549200_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3399\/bjgp20X708053","article-title":"Diagnosis and management of hypertension in adults: NICE guideline update 2019","volume":"70","author":"Jones","year":"2020","journal-title":"Br J Gen Pract"},{"key":"2025011107303549200_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14656566.6.2.275","article-title":"The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies","volume":"6","author":"Weder","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"2025011107303549200_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/hr.2011.216","article-title":"Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial","volume":"35","author":"Ogihara","year":"2012","journal-title":"Hypertens Res"},{"key":"2025011107303549200_bib9","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/01.hjh.0000939140.38251.59","article-title":"Long-term event rates, risk factors, and treatment pattern in patients qualifying for dual blood pressure-lowering therapy: an observational study in 1.4 million individuals","volume":"41","author":"Coca","year":"2023","journal-title":"J Hypertens"},{"key":"2025011107303549200_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"Br Med J"},{"key":"2025011107303549200_bib11","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"},{"key":"2025011107303549200_bib12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/eurheartj\/eht533","article-title":"Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients","volume":"35","author":"Rapsomaniki","year":"2014","journal-title":"Eur Heart J"},{"key":"2025011107303549200_bib13","article-title":"Definition of hypertension and pressure goals during treatment (ESC-ESH Guidelines 2018)","volume":"17","author":"Ramzy","year":"2019","journal-title":"Eur Soc Cardiol J"},{"key":"2025011107303549200_bib14","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1161\/HYPERTENSIONAHA.120.14648","article-title":"Evidence for the universal blood pressure goal of&lt;130\/80\u00a0mm Hg is strong: controversies in hypertension-con side of the argument","volume":"76","author":"Kaul","year":"2020","journal-title":"Hypertension"},{"key":"2025011107303549200_bib15","first-page":"1547","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume-title":"N Engl J Med","author":"ONTARGET Investigators","year":"2008"},{"key":"2025011107303549200_bib16","first-page":"24","article-title":"ACE inhibitors and ARBs: one or the other\u2014not both\u2014for high-risk patients","volume":"58","author":"Misra","year":"2009","journal-title":"J Fam Pract"},{"key":"2025011107303549200_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2019.06.005","article-title":"Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"216","author":"Cannon","year":"2019","journal-title":"Am Heart J"},{"key":"2025011107303549200_bib18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamacardio.2017.2289","article-title":"Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"2","author":"Cannon","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025011107303549200_bib19","author":"Python Software Foundation"},{"key":"2025011107303549200_bib20","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2147\/PPA.S368784","article-title":"A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider","volume":"16","author":"Hamrahian","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"2025011107303549200_bib21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in hypertension","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ Res"},{"key":"2025011107303549200_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"2025011107303549200_bib23","doi-asserted-by":"crossref","first-page":"e0245610","DOI":"10.1371\/journal.pone.0245610","article-title":"Effect of patient and treatment factors on persistence with antihypertensive treatment: a population-based study","volume":"16","author":"Malo","year":"2021","journal-title":"PLoS One"},{"key":"2025011107303549200_bib24","doi-asserted-by":"crossref","first-page":"e4908","DOI":"10.1097\/MD.0000000000004908","article-title":"Persistence to antihypertensive drug classes: a cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD)","volume":"95","author":"Qvarnstr\u00f6m","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025011107303549200_bib25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/PPA.S225444","article-title":"Fixed versus free combinations of antihypertensive drugs: analyses of real-world data of persistence with therapy in Italy","volume":"13","author":"Putignano","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2025011107303549200_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jch.13426","article-title":"Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications","volume":"21","author":"Dipette","year":"2019","journal-title":"J Clin Hypertens"},{"key":"2025011107303549200_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025011107303549200_bib28","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","article-title":"Patient selection for intensive blood pressure management based on benefit and adverse events","volume":"77","author":"Bress","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025011107303549200_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"2025011107303549200_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11886-020-01400-3","article-title":"Medication non-adherence: a major cause of resistant hypertension","volume":"22","author":"Hamrahian","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2025011107303549200_bib31","doi-asserted-by":"crossref","first-page":"106557","DOI":"10.1016\/j.phrs.2022.106557","article-title":"Therapeutic concordance improves blood pressure control in patients with resistant hypertension","volume":"187","author":"Trimarco","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025011107303549200_bib32","doi-asserted-by":"crossref","first-page":"e11121","DOI":"10.1097\/MD.0000000000011121","article-title":"Clinical inertia in the pharmacological management of hypertension: a systematic review and meta-analysis","volume":"97","author":"Milman","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025011107303549200_bib33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"2025011107303549200_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13098-020-00559-7","article-title":"Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review","volume":"12","author":"Andreozzi","year":"2020","journal-title":"Diabetol Metab Syndr"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae048\/58717614\/pvae048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/697\/58717614\/pvae048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/697\/58717614\/pvae048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T07:30:54Z","timestamp":1736580654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/8\/697\/7710108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae048","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,9]]}}}